Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil.

摘要: 5-Fluorouracil (5-FU)-associated neurotoxicity is uncommon; symptoms may occur abruptly or more gradually during the course of chemotherapy. Peripheral neuropathy with 5-FU therapy has only rarely been reported. Two patients treated in a phase I trial oral 5-FU, leucovorin and eniluracil, an inhibitor dihydropyrimidine dehydrogenase (DPD), developed delayed onset unsteady gait reduced sensation legs. Magnetic resonance imaging scans brain neurologic examination did not support CNS basis for condition. Electromyograms nerve conduction studies revealed sensorimotor polyneuropathy. Other common etiologies peripheral were excluded. The neurological condition these stabilized after dose reduction partial resolution occurred when protocol was stopped. Although complicate therapy, unexpected. Patients DPD deficiency conventional doses typically develop acute toxicity shortly accompanied by extremely high systemic exposure to 5-FU. normal clearance also experience toxicity, particularly high-dose schedules, both parent drug its catabolites be contributory. Since profoundly inhibited eniluracil two patients, it likely that active metabolites contributing factors neuropathy.